

Luc Y Dirix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6124762/publications.pdf>

Version: 2024-02-01

24
papers

1,922
citations

858243

12
h-index

721071

23
g-index

25
all docs

25
docs citations

25
times ranked

3864
citing authors

#	ARTICLE	IF	CITATIONS
1	Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 583-591.	1.1	5
2	Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 437-444.	1.1	16
3	Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1195-1205.	0.4	12
4	Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 499-506.	2.0	6
5	The use of simulation-CT™s as a coronavirus disease 2019 screening tool during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 151, 17-19.	0.3	3
6	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020, 20, 430.	1.1	4
7	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686.	1.1	564
8	Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. <i>European Urology</i> , 2017, 72, 192-200.	0.9	106
9	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. <i>Clinical Therapeutics</i> , 2016, 38, 2286-2299.	1.1	42
10	Neratinib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2243-2248.	0.9	10
11	LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. <i>Molecular Oncology</i> , 2016, 10, 1363-1373.	2.1	23
12	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	1.1	25
13	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	0.9	44
14	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015, 362, 36-44.	3.2	41
15	Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 749-760.	1.4	5
16	Management of pulmonary toxicity associated with targeted anticancer therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1695-1707.	1.5	15
17	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. <i>Cancer Letters</i> , 2015, 356, 872-879.	3.2	28
18	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703

#	ARTICLE	IF	CITATIONS
19	Bevacizumab beyond progression in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1190-1191.	5.1	2
20	Vismodegib: a promising drug in the treatment of basal cell carcinomas. <i>Future Oncology</i> , 2012, 8, 915-928.	1.1	8
21	VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 805-808.	1.2	3
22	Re: Anti-“Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2009, 101, 895-896.	3.0	6
23	Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 389-395.	2.9	175
24	EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA. , 1997, 182, 211-216.		76